Press release BoxID: 116713 (Eurofins Genomics GmbH)
  • Eurofins Genomics GmbH
  • Anzinger Str. 7a
  • 85560 Ebersberg
  • Contact person
  • Jutta Huber
  • +49 (8092) 8289-930

MWG Biotech / Eurofins Medigenomix develop new software to optimize sequences for gene synthesis

(PresseBox) (Ebersberg, ) MWG Biotech / Eurofins Medigenomix develop GENEius software with unique features for gene synthesis.

MWG Biotech, through their alliance with Eurofins Medigenomix, has a long track record in synthetic gene production. Based on advanced techniques and optimized processes, the companies offer fast and reliable gene synthesis services, where all process steps including oligonucleotide production, design and processing of gene synthesis and final quality control of the genes are handled in-house.

Several years of experience in gene synthesis was used to develop new sequence optimization algorithms. The resulting software “GENEius”
provides enhanced functions, such as the automatic adaptation of the codon usage, which can optimize DNA sequences for protein expression in a target organism. GENEius also prevents direct or indirect repeats and hairpin structures in the optimized sequence, in that way solving problems during transcription or translation. Unlike other codon adaptation programs, GENEius does not affect codon adaptation quality when optimising for other features.

Dr. Stefan Blickling, Head of Sales Europe, says: “The intelligent features of this sophisticated software help us to strengthen our position as the high quality provider of synthetic genes. It provides us with a tool to design products for our customers, so that they can achieve optimal results from their experiments.”

Eurofins Genomics GmbH

MWG Biotech (ISIN: DE0007300105) ist ein internationaler Anbieter von Genomik-Produkten und Dienstleistungen aus den Bereichen DNA/siRNA Synthese (Produktion synthetischer Genabschnitte) und DNA Sequenzierung (Bestimmung der genetischen Information im Erbgut). Mit starker Kundenorientierung, schnellem Service und qualitativ hochwertigen Produkten aus drei Produktionsstätten in Deutschland, den USA und Indien schafft das Unternehmen die Grundlagen für Erfolg in den Life Science Märkten weltweit.